Several lines of evidence support the presence of dosage-sensitive genes on chromosome 21 that regulate leukemogenesis and hematopoiesis. We report a detailed clinical and molecular characterization of three patients with chronic thrombocytopenia caused by distinct constitutional microdeletions involving chromosomal region 21q22.12.
Introduction
Acquired and constitutional structural genomic aberrations leading to the activation of oncogenes or haploinsufficiency of tumor suppressor genes are well-known pathogenic mechanisms in cancer. The predisposition for leukemia and myelodysplasia (MDS) 1, 2 and the common hematological abnormalities 3 seen in children with trisomy 21
suggest that dosage-sensitive genes on chromosome 21 are involved in leukemogenesis and hematopoiesis. The "leukemogenic" role of an additional chromosome 21 was further supported by showing the selective involvement of trisomic cells with leukemia in patients with trisomy 21 mosaicism. 4 In addition, trisomy/polysomy 21and translocations that disrupt the RUNX1 gene on chromosome 21q22 are nonrandom and are among the most frequent acquired chromosomal abnormalities in acute lymphoblastic leukemia (ALL) and acute myelocytic leukemia (AML). [5] [6] [7] This dosage effect is also seen in a subtype of ALL patients with intrachromosomal amplification of chromosome 21
encompassing the RUNX1 gene (iAMP21) who have poor outcome. 8 The significant role of RUNX1 in megakaryopoiesis and leukemogenesis was further supported by the finding that haploinsufficiency of the RUNX1 gene is the genetic basis of the autosomal dominant familial platelet disorder with predisposition to acute myelogenous leukaemia (FPD/AML, MIM 601399). 9 Similar to patients with the FPD/AML syndrome, there was an approximately 15% reduction in the number of platelets in the Runx1 +/-mice, 10 but the development of AML could not be recapitulated in these mice. 10, 11 In addition, somatic mutations in RUNX1 and its cofactor CBFB are frequently found in acute leukemias and MDS. 12, 13 For personal use only. on September 24, 2017 . by guest www.bloodjournal.org From
Here we present the molecular analysis and fine mapping of constitutional microdeletions on 21q encompassing the RUNX1 gene in three patients with chronic thrombocytopenia. One of the three patients developed AML at the age of 6 years. In addition, the patients had growth restriction, dysmorphic features, and variable degree of developmental delay.
Materials and Methods
The parents of all three subjects gave informed consent to participate in human subjects protocols approved by the Institutional Review Board (IRB) of Baylor College of Medicine. Patient 1 was enrolled on IRB-approved protocol entitled: "The Molecular Basis of Familial Cancer Predisposition Syndromes". Patients 2 and 3 were enrolled on IRB-approved protocol entitled: "Use of microarrays (DNA chips) for global detection of cytogenetic abnormalities by comparative genomic hybridization". Both studies include forms that specifically allow parents to provide consent for the use of photographs for publication. The informed consents were provided according to the Declaration of Helsinki.
Cytogenetic and fluorescence in situ hybridization (FISH) analyses
Chromosome analysis of phytohemagglutinin (PHA)-stimulated peripheral blood lymphocytes (for all patients) and of bone marrow (for patient #1) was performed by GTG-banding analysis using standard cytogenetic laboratory procedures. FISH analysis using probes specific for ETO and RUNX1 genes and other specific probes for chromosome 21 were performed in PHA stimulated peripheral blood sample obtained from the patients. DNA for home brewed FISH probes was extracted and directly labeled according to the manufacturers' instructions (Vysis). 
Results

Clinical Reports
In this report, we describe the clinical and molecular characterization of three patients with chronic thrombocytopenia, dysmorphic features (see Supplementary   Figure) , congenital anomalies and variable developmental delay. Table 1 provides a summary of the clinical features of all three patients. The average platelets counts were similar in all three patients; 78,000, 60,000, 74,000 in patients #1, #2, and #3, respectively. Prior to the cytogenetic analyses described below all three patients had extensive clinical work-ups, e.g. DEB breakage, which failed to reveal the cause of their thrombocytopenia. In patient #3, the platelet count was only requested after the karyotype and microarray analysis revealed that the deletion encompassed the RUNX1 Figure   2B ). Parental FISH analysis with the same BAC revealed a normal pattern in the mother.
In the father, the BAC hybridized to one chromosome 21 and a second hybridization signal on the long arm of one chromosome 11( Figure 2B ). The same insertional rearrangement was found in one of patient #2's four siblings.
Karyotype analysis in patient #3 at birth showed a deletion at 21q22.1. The mother's karyotype was normal but the father was not available for analysis. Based on the molecular results described below, FISH analysis was performed using two BAC clones from 21q: RP11-17O20 more distal and RP11-92D3 more proximal. In 15% of interphase nuclei there was one signal for both BACs and in 85% there were two signals for the proximal BAC and a single signal for the distal (more telomeric) BAC (data not shown).
The clinical CMA result for patient #3 also revealed a loss of copy number with 11 clones (from RP11-17O20 to clone RP4-639D23) that encompass at least 11 megabases on 21q22.1 (data not shown). The T-statistic values for centromeric clones were higher than for the more telomeric clones consistent with the finding from FISH analysis that there is a mixed population of cells with different size microdeletions.
High-resolution genomic analyses by 244K array-CGH
Patient #1 had high resolution analysis using the Affymetrix 50K SNPchip (data not shown) which was consistent with the Agilent array data described below.
Subsequently, all three patients had research analysis using the Agilent 244K Whole Human Genome CGH Microarray in order to better define the extent of deletion. The 
Discussion
We report three patients with chronic thrombocytopenia associated with multiple congenital anomalies, dysmorphic features, growth restriction, and developmental delay.
One of the three patients developed AML at the age of 6 years. All three patients demonstrated constitutional microdeletions encompassing band 21q22.12. The deletions were variable in size and therefore were detected clinically by different techniques including routine karyotype for the largest deletion, clinical array-CGH, and targeted RUNX1, CLIC6, DSCR1, and a portion of KCNE1 ( Figure 4A ).
The FISH analysis using a RUNX1 probe on patient #1 demonstrated that the microdeletion was constitutional and not secondary to leukemia development. Both FISH and array-CGH demonstrate that the trisomic chromosome in the leukemia cells contains the RUNX1 deletion. This finding provides strong evidence that although deletion of the RUNX1 locus is responsible for the thrombocytopenia and predisposition to AML, other dosage sensitive genes on chromosome 21 also play a role in development of leukemia. In addition, the leukemic clone contains duplication of 7p that has not been previously reported in AML (http://www.cancerindex.org). Interestingly, the duplicated region contains the cluster of HOX genes which have been implicated in AML pathogenesis. 16, 17 In all three cases, the subjects had undergone extensive evaluations including a variety of different molecular and biochemical analyses, chromosome fragility testing, and muscle biopsy (see Supplemental Data). Clinical use of array-CGH analysis earlier in the diagnostic work-up for syndromic thrombocytopenia will allow for rapid identification of the causative deletion.
The molecular basis of the deletion was different in all three patients with patient #1 resulting from a de novo deletion, #2 from a paternal insertional translocation, and #3 with likely postzygotic deletions resulting in mosaicism for two different sized deletions.
Patient #3 had thrombocytopenia despite the fact that only 15% of the cells were deleted 
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KCNE are responsible for prolonged QT and sensorineural hearing loss (Jervell and Lange-Neilsen syndrome; JLNS1; MIM 220400). 23 Interestingly, although these abnormalities (including measurement of the QT interval) were not found in our patients, a cardiology evaluation is indicated in this microdeletion syndrome given that not all patients with LQTS show an increased QT interval at rest.
The molecular data on our patients provide additional support for the significant role of RUNX1 haploinsufficiency in the development of thrombocytopenia as it results from a complete gene deletion as opposed to any potential dominant negative effect from point mutations as previously described in FPD/AML. 9 The hematological abnormalities, clinical history, physical findings, and molecular defects in our patients add to our understanding of the heterogeneous group of hereditary thrombocytopenias. 24 In particular, we demonstrate the clinical utility of array-CGH technology in the assessment of patients with thrombocytopenia and congenital anomalies and/or developmental delay.
Conclusion
Deletions encompassing the RUNX1 gene on 21q22.12 are responsible for syndromic thrombocytopenia and predisposition to AML. Patients with this contiguous gene syndrome also exhibit dysmorphic features, developmental delay, and growth restriction ( Figure 4B ). Molecular analysis of leukemia samples from one patient deleted for RUNX1 confirm that haploinsufficiency of RUNX1 is associated with AML development but that other genes on chromosome 21 also play a role in trisomy 21 associated with AML. We predict that a wider clinical application of array-CGH will significantly improve our ability to provide a definitive diagnosis for patients with
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